Serina Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Serina Therapeutics, Inc. (SER) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $33.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2024-11-12
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $33.00K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $65.00K.
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $98.00K.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $33.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2024-09-30 | $33.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $65.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $98.00K 10-Q · filed 2024-05-14 |
| 2023-09-30 | $33.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $66.00K 10-Q · filed 2023-08-14 |
| 2022-12-31 | $98.00K 10-Q · filed 2023-05-12 |
| 2022-09-30 | $32.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $65.00K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $98.00K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |